glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Effects of Once-Weekly on Disease by KDIGO Risk Category in the SUSTAIN 6 CKJ REVIEW GLP-1 receptor agonists
Description
While the full picture is still emerging, the breadth of these effects underscores why expectations for this drug class have soared
Surging focus on developing personalized therapies is expected to offer lucrative opportunities in the market during the forecast period
Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US
FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
